Speakers - Sachs Associates

CONTACT
Roel Q. J Schaapveld, PhD, MBA
Chief Executive Officer
ADDRESS
Hugo R. Kruyt building
Padualaan 8
3584 CH Utrecht
The Netherlands
TELEPHONE
+31 30 253 2386
FAX
+31 30 253 9176
EMAIL
schaapveld
@interna-technologies.com
YEAR FOUNDED
December 2006
InteRNA Technologies B.V.
www.interna-technologies.com
FINANCIAL SUMMARY
Investors: • Aglaia Oncology Fund • PPM Oost
COMPANY PROFILE
InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel
breakthrough cancer therapies based on the unique functions of its proprietary miRNAs.
InteRNA’s drug development programs aim at developing miRNA-based therapeutics that control genes
connected in signal transduction pathways and biological processes that are known to play a role in cancer
initiation, progression and metastasis.
InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens,
using its proprietary lentiviral-based miRNA expression library, which is the largest currently available.
With the Company’s proprietary miRNA expression database (generated through deep sequencing) and additional
technologies (like RNAseq, bioinformatics, in vivo models) in place to identify the downstream regulated proteins
for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their
biomarkers quickly towards the clinic.
MANAGEMENT
Roel Q.J. Schaapveld, PhD, MBA, Chief Executive Officer
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS